(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue - 2South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- 3A Couple of Modest Guitars for 2024
- 4Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- 5German official report: Teen social media ban faces legal hurdles
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Become the best at Discussion: 6 Procedures for Progress
- The Job of a Land Legal counselor in Property Exchanges
- Treasure trove found in Egyptian tomb solves ancient mystery
- The most exciting exoplanet discoveries of 2025
- Beddings of 2024: Track down Your Ideal Fit for a Tranquil Rest
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
